Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Anti-IgE monoclonal antibodies

16 evidence topics · 14 sources

Omalizumab as add-on treatment after high-dose antihistamines: 2026 international guideline
Week 12 results with omalizumab 300 mg after antihistamines up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists
Week 12 outcomeOmalizumab 300 mg (n = 252)Placebo (n = 83)
Change from baseline in UAS7, mean (95% CI)“−19.0 (−20.6 to −17.4)”“−8.5 (−11.1 to −5.9)”
UAS7 ≤6, no. (%)“132 (52.4)”“10 (12.0)”
UAS7 = 0, no. (%)“85 (33.7)”“4 (4.8)”
Drug survival and reasons for discontinuation: meta-analysis of 8 observational studies

“Observational clinical studies that reported on time to discontinuation or drug survival outcomes for omalizumab in patients with CU were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Eight studies comprising 4516 patients with CU (3167 female individuals [70.1%]; 3276 with chronic spontaneous urticaria [CSU]) were included. The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%). Early discontinuation was primarily due to well-controlled disease. Discontinuation due to adverse events was uncommon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The results of this systematic review and meta-analysis suggest that omalizumab demonstrates long-term drug survival in CU, with discontinuation more often due to disease control than adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Omalizumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update

“We systematically synthesized the comparative benefits and harms of systemic treatments for chronic urticaria.” (opens the source at this quote in a new tab)

“As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines” (opens the source at this quote in a new tab)

“Random effects Bayesian network meta-analyses addressed urticaria activity (comprising itch and wheal scores), angioedema activity, health-related quality of life, and adverse events.” (opens the source at this quote in a new tab)

“We included 93 studies (n = 11,398; mostly adult and adolescent participants across 83 randomized trials and 10 nonrandomized studies) that evaluated 42 interventions. With high certainty, standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective for improving multiple patient-important outcomes.” (opens the source at this quote in a new tab)

“Standard-dose omalizumab (MD −8.37 [95% CrI −10.28 to −6.46]; high certainty), and remibrutinib (MD −7.65 [95% CrI −11.75 to −3.54]; high certainty) are among the most effective, while low-dose omalizumab (MD −5.25 [95% CrI −7.83 to −2.68]; high certainty) is among the intermediate effective.” (opens the source at this quote in a new tab)

“Standard-dose omalizumab (MD 8.75% more [95% CrI 1.93% to 15.56% more]; high certainty) and remibrutinib (MD 15.00% more [95% CrI 3.16% to 26.84% more]; high certainty) are among the most effective.” (opens the source at this quote in a new tab)

“Nonrandomized data (n = 149) suggest that 69% (95% CI 59% to 78%) of patients with disease refractory to standard-dose omalizumab may experience response (ie, UAS7 ≤ 6 or Urticaria Control Test [UCT] ≥ 12) with higher doses or more frequent administration.” (opens the source at this quote in a new tab)

“High-certainty evidence demonstrates that omalizumab (OR 0.92 [95% CrI 0.58 to 1.45]; RD 0.2% less [95% CrI 1% less to 1% more]) is not different from placebo” (opens the source at this quote in a new tab)